Gemtesa is THE FIRST AND ONLY BETA-3 AGONIST THAT DOES NOT CAUSE CYP2D6 DRUG INTERACTIONS1

OAB patients take an average of 12–14 medications annually,* many of which are metabolized by CYP2D62-4

Common comorbidities in patients with OAB include:

  • Hypertension
  • Depression
  • Diabetes
79.3%

79.3% of patients taking any OAB medication also take medicine metabolized through the CYP2D6 pathway3†

Patient ready to take a pill.

Regularly prescribed medications that metabolize on CYP2D64-8:

SSRIs/SNRI
  • Fluoxetine
  • Duloxetine
  • Paroxetine
BETA-BLOCKERS
  • Metoprolol
  • Carvedilol
  • Propranolol
TRICYCLIC
ANTIDEPRESSANTS
  • Amitriptyline
  • Nortriptyline
  • Doxepin
ATYPICAL
ANTIPSYCHOTICS
  • Aripiprazole
  • Risperidone
  • Olanzapine

GEMTESA has not been studied in concomitant use with these medications.

Digoxin drug interaction was identified with GEMTESA. Measure serum digoxin concentrations before initiating GEMTESA. Monitor serum digoxin concentrations to titrate digoxin dose to desired clinical effect. Continue monitoring digoxin concentrations upon discontinuation of GEMTESA and adjust digoxin dose as needed.1

*Data from 2 studies. The first study examined patients (65.4% were 75 years old) with OAB who had concurrent medical conditions and received concomitant medications (n=415). The second study analyzed the number of OAB medications taken by patients 65 years old during a more than 1-year period (n=1,801,457).2,3

Data from IQVIA PharMetrics® Plus (Pharmetrics) between November 2012-September 2019 that evaluated adult patients taking a medication for OAB (N=838,844) and subsequently prescribed any prespecified CYP2D6 substrate (n=106).3

CYP2D6=cytochrome P450 2D6; SNRI=serotonin-norepinephrine reuptake inhibitor; SSRI=selective serotonin reuptake inhibitor.

But wait, there’s more!

GEMTESA is the first and only beta-3 agonist with
urgency data in its label1

Learn more about GEMTESA, a selective beta-3 adrenergic agonist
See MOA
Patient. Learn about the mechanism of action (MOA) of GEMTESA®.
 

References: 1. GEMTESA. Prescribing information. Urovant Sciences GmbH; 2020. Accessed January 4, 2021. https://gemtesa.com/sites/default/files/gemtesa-prescribing-information.pdf 2. Ganz ML, Liu J, Zou KH, Bhagnani T, Luo X. Real-world characteristics of elderly patients with overactive bladder in the United States. Curr Med Res Opin. 2016;32(12):1997-2005. doi:10.1080/03007995.2016.1226167 3. Data on file. Urovant Sciences GmbH. 4. Hansten PD, Horn JR. The Top 100 Drug Interactions: A Guide to Patient Management. H&H Publications; 2019. 5. ClinCalc DrugStats Database. The top 300 of 2021. Accessed January 7, 2021. https://clincalc.com/drugstats/Top300Drugs.aspx 6. ClinCalc DrugStats Database. Top 250 drugs: drug list by therapeutic category. Accessed January 7, 2021. https://clincalc.com/downloads/top250drugs-druglist.pdf 7. ClinCalc DrugStats Database. Doxepin hydrochloride. Accessed March 14, 2021. https://clincalc.com/DrugStats/Drugs/DoxepinHydrochloride 8. ClinCalc DrugStats Database. Tricyclic antidepressants. Accessed March 14, 2021. https://clincalc.com/DrugStats/TC/TricyclicAntidepressants 9. Staskin D, Frankel J, Varano S, et al. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316-324.